News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Hospitalization Not Cut by Gilead Sciences, Inc. Heart Drug-Study
April 5, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NEW ORLEANS, April 4 (Reuters) - Gilead Sciences Inc's (GILD.O) heart drug Ranexa, while found to be effective in reducing chest pain in refractory angina patients, failed to cut hospitalizations in a small 100-patient study.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Gilead Sciences, Inc.
MORE ON THIS TOPIC
Lung cancer
Merck, Daiichi Sankyo Stage Lung Cancer Rally With ‘Strong’ Pivotal Data for I-Dxd
September 8, 2025
·
2 min read
·
Tristan Manalac
Psychedelics
With Lykos MDMA Rejection Letter Out, MAPS Founder Decries ‘Change of the Goal Posts’
September 5, 2025
·
3 min read
·
Dan Samorodnitsky
Immunology and inflammation
Sanofi’s Anti-OX40 Blocker Falls ‘Well Below Expectations’ in Phase III Eczema Study
September 5, 2025
·
2 min read
·
Tristan Manalac
FDA
FDA Drops Another Cache of Heavily Redacted Rejection Letters, Promises Future ‘Real-Time’ Access
September 4, 2025
·
4 min read
·
Annalee Armstrong
